Does BREVAGenplus Really Make a Difference?

I had a somewhat mixed reaction to Genetic Technologies’ (ASX : GTG) recent, rather breathless update about the progress of its BREVAGenplus breast cancer risk test (the product website is worth a read for basic background). There can be little doubt that we are entering the era of genetic testing in order to improve the economics of…

The Questionable Ethics of Anisina

I really appreciate the value that many of the Long Tail readers bring to this site, and I’d particularly like to thank a couple of followers that sent me (both publicly and privately) the link to the Kids’ Cancer Project website that talks about Anisina (I have also take a PDF of it in case the page(s) gets…

Starpharma : Love the rubbers, less keen on the drugs…

Over the years, a number of people have asked me what I think about StarPharma (ASX : SPL), and the answer has changed a lot over time. Overall it’s a company I haven’t really bothered spending much time looking at because after its failed Phase III for VivaGel, I sort of figured it was burnt toast. The general consensus…

Regeneus RGSH4K : Highly Dubious

I have been struggling how to address this one, ever since Regeneus announced its “approval” to run its RGSH4K trial. To be clear to readers unfamiliar with the circumstances, this is not an approval from the Therapeutic Goods Administration (TGA), this is merely the institutional ethics approval for the clinical site running the study (Regeneus has not…

HotCopper – No Longer

Over the past few weeks I have endured an extraordinary amount of abuse on HotCopper. Unfortunately when I try to defend myself with reference to my blog, HotCopper deletes my commentary because it is construed as “advertising.” On one occasion I did post a URL and so I accepted the temporary account suspension. However when others…